Article
GSK To Acquire Trispecific T Cell-Engager For Multiple Myeloma From Chimagen Biosciences
GSK plc has entered into an agreement to acquire a trispecific T cell-engager from Chimagen Biosciences, targeting multiple myeloma treatment with improved tolerability. The innovative therapeutic approach aims to bind T cells while simultaneously targeting two tumor-associated antigens, potentially enabling broader adoption in earlier treatment stages. This marks GSK's second acquisition from Chimagen, following their October 2024 deal for a dual CD19/CD20-targeted TCE.
Goodwin Procter LLP